Supernus Pharmaceuticals Set to Participate in Key Conference
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) is getting ready to showcase its innovations at a significant healthcare event. Jack A. Khattar, who holds the position of President and CEO, is scheduled to take part in a fireside chat at the upcoming annual Piper Sandler Healthcare Conference. This conference is known for bringing together key players in the pharmaceutical and healthcare industries.
Details About the Conference
The conference is set to take place in a prominent location, where leaders in health and medicine will gather to exchange ideas and insights. Jack will present on the progress and vision of Supernus Pharmaceuticals as they focus on developing treatments targeting central nervous system (CNS) diseases.
Engagement Opportunities for Investors
Investors looking to connect with Supernus management during this event are encouraged to arrange meetings through the conference’s coordinator. With the rapid evolution of the biopharmaceutical landscape, dialogues during such conferences could uncover potential partnerships and insights into the company’s future.
Supernus’ Innovative Portfolio
The company has carved a niche in the biopharmaceutical realm by specializing in products designed for CNS disorders. Their product range addresses various conditions including epilepsy, migraines, and ADHD, alongside other serious disorders impacting daily life.
Focus on Research and Development
Supernus is committed to pushing the boundaries of treatment options. Their R&D efforts are concentrated on novel therapies, aiming to enhance the quality of life for individuals suffering from CNS issues. This relentless pursuit of innovation is part of what they will be discussing during the conference.
Listening to the Presentation
For those unable to attend the live presentation, Supernus will provide an audio webcast accessible through their website. There will also be an archive available for 60 days post-conference, ensuring that stakeholders can stay informed about the company’s developments and announcements.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the development and commercialization of therapeutic products for CNS diseases. With an expansive portfolio, they aim to deliver effective treatments while continually exploring new market opportunities.
Company Leadership
Leadership at Supernus, spearheaded by Jack A. Khattar and Timothy C. Dec, focuses on steering the company towards increased profitability and innovation. Their experience and strategic vision are crucial as they navigate the complex healthcare marketplace.
Contact Information
For inquiries, Supernus can be reached directly by calling (301) 838-2591 or through their investor relations contact:
Peter Vozzo
ICR Healthcare
(443) 213-0505
Peter.Vozzo@westwicke.com
Frequently Asked Questions
What is the purpose of the Piper Sandler Healthcare Conference?
The conference serves as a platform for biopharmaceutical companies to showcase their innovations and discuss strategies with investors and industry leaders.
Who is representing Supernus Pharmaceuticals at the conference?
Jack A. Khattar, the President and CEO, will be participating in a fireside chat during the event.
What areas does Supernus Pharmaceuticals focus on?
Supernus specializes in developing and commercializing products for various central nervous system diseases.
Will there be an opportunity to listen to the presentation later?
Yes, Supernus will provide a live audio webcast of the presentation, which will also be archived for future access.
How can investors contact Supernus Pharmaceuticals?
Investors can contact the company by phone or reach out to their investor relations person for further information.
